Contineum Therapeutics, Inc. (CTNM) has been able to do well to advance the use of an LPA1R antagonist for the treatment of neuroinflammatory disorders in a phase 1 healthy volunteer study. Why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results